Log In
BCIQ
Print this Print this
 

HTI-101

  Manage Alerts
Collapse Summary General Information
Company Hemodynamic Therapeutics Inc.
DescriptionLow-dose combination of amiloride and spironolactone
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationHypertension
Indication DetailsTreat hypertension in obese adults
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today